Veracyte sells diagnostic tests, many for cancer, to physicians and healthcare providers from South San Francisco, California. VCYT reports earnings on Wed, Nov 4, 2026. Analyst consensus is Buy, based on the latest ratings from 7 firms (5 buy, 1 hold, 1 sell). In the past 30 days there were 2 dark pool prints.
Prices, price targets and earnings estimates for VCYT are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VCYT is in one of them and how their past VCYT trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Veracyte
Veracyte is a diagnostic company based in South San Francisco, California. It develops and sells tests, many of them for cancer, that help physicians make decisions about patient care. Its best-known product is the Prosigna breast cancer test, which is available in international markets and runs on the nCounter Analysis System. The company also offers thyroid testing services and performs many of its tests in its own laboratories for physicians and healthcare providers.
